Compare FSI & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSI | ELOX |
|---|---|---|
| Founded | 1991 | 1999 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.7M | 60.3M |
| IPO Year | 2000 | 2013 |
| Metric | FSI | ELOX |
|---|---|---|
| Price | $6.25 | $12.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 12.6K | ★ 19.7K |
| Earning Date | 11-13-2026 | 08-12-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | N/A | ★ 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,494,325.00 | N/A |
| Revenue This Year | $24.09 | N/A |
| Revenue Next Year | $60.56 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.85 | $10.00 |
| 52 Week High | $9.12 | $23.40 |
| Indicator | FSI | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 51.74 | 41.68 |
| Support Level | $5.94 | $10.74 |
| Resistance Level | $6.61 | $14.65 |
| Average True Range (ATR) | 0.19 | 1.15 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 41.27 | 43.97 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.